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1102-22 Persistently Elevated Levels of Soluble CD40 Ligand 
One Month After Percutaneous Coronary Angioplasty 
Correlate With Six-Month Restenosis 
&&g@ I CAlltier, Jean Gregoire, Michel Joyal, Jean-Claude Tardif, Montreal Heart 
Institute, Montreal, Quebec, Canada. 
Background.Balloon angioplasty (BA) induces an early inflammatory reaction and 
periprocedural CRP correlates with late restenosis.The aim of the current study was to 
charactertze the type and duration of inflammatory reaction after BA, and to identify more 
specific inflammatory markers correlating with restenosis. Methode.We studied 56 con- 
secutive patients (pts) with stable coronary artery disease who underwent successful BA. 
Blood was drawn just before BA. at l-month, and at 6.month follow-up. We evaluated 
CD40 ligand (sCD40L), vascular cell adhesion molecule-l (VCAM-1). and matrix metal- 
loproteinase-2 (MMP-2). All pts underwent 6-month follow-up angiography. Results. Lev- 
els of both sCD40L and MMP-2 increased from pm-PTCA to 1 month, and decreased 
between 1 month and 6 months (Table). Plasma levels of sCD40L at l-month correlated 
with angiographic late loss (r -0.46, p=O.OOl). A receiver operating characteristic (ROC) 
curve showed that sCD40L was a good predictor of 6-month dichotomous angiographic 
restenosis (area under curve 0.75. 95% Cl 0.61-0.68). with a cutpoint of 4.0 ngil or more 
having a sensitivity and specificity of 0.76 and 0.72. Conclusions. Our results imply that 
inflammation persists for at least 1 month after EA. This suggest that anti-inflammatory 
interventions to prevent restenosis should be active for more than 1 month post BA. The 
predictive value of sCD40L may indicate the relevance of this pathway as a therapeutic 
target for restenosis prevention. 
Serum Levels of Inflammatory Markers After BA 
sCD40L 
sMMP-2 
sVCAM-1 
hs-CRP 
pre-BA 1 month F-up 
4.1kO.6 5.6eO.6 
1133.6t36.6 1326.1i36.6 
995.2i67.3 1044.7+67. 
5.1+10.9 3.5i3.6 
6-month F-up 
4.2+0.6 
1163.1+38.6 
1064.7e67.5 
3.3t3.6 
p value 
p<o.o2 
<0.0001 
0.07 
“S 
1102-23 Slochemlcal Markers of Myocardlal Injury in Patients 
With Stable Anglna Pectoris Undergoing Successful 
PTCA: Clinical Importance? 
v, Jan Ravkilde, Dept. ofCardiology Skejby University Hospital, Aarhus, 
Denmark, Dept. of Cardio/ogy Aalborg University Hospital, Aalborg, Denmark. 
Objective To evaluate the importance of increases in biochemical markers in patients 
with stable angina pectorfs (SAP)undergoing successful elective (PTCA) concerning clin- 
ical usefulness and prognostic value 
Methods 544 consecutive patients with SAP undergoing elective successful PTCA 
according to ACCIAHA guidelines. We measured the concentration of CKMBmass. 
troponin T (TnT). 3 different troponin I’s and CKMB and CKtotal activity. Bloodsampling 
prePTCA, 6 and 16 hours after PTCA. 
Results Number of stenoses treated per patient median 1.45 (range l-4). Biochemical 
marker positive and median (range) as given in the table. At 1 month the total events 
were 1.6% (g/544). all nine events were UAP. At 3 months the total events were 3.7 % 
(20/544) with 2 cardiac death, 1 AMI. 17 UAP. At 6 months the total events were 
increased to 6.1 % with 3 cardiac deaths, 3 AMI, 27 UAP. 
Events % (cardiac death, AYl,mPTCA, 
CABG,raadm.UAP) 
1 month tmonths Gmonths 
Marker cut-off Positive Positive negatwe Positive negstbve Positive negative 
VSIUSS >(median 
(range)) 
CKMBma 10.0 ng/ 6.6% 4,2 1,4 12,5” 28 20.1” 4,6 
ss mL (27.5 (10.4-114)) 
TnT 0.10 ng/ 6.5% 2,2 I,6 10,9 3,O 19,6” 4,6 
mL (0.26 
(0.1 -3 06)) 
Tfll- 0.5 nq/rnL 15.7% 1,2 I,6 I,2 3.1 11,9’ 5,1 
Beckm. (1.09 (0.54-100)) 
Tnl-Ortho 1 .O nglmL 6.8% 2,i 1,6 8,5# 3.2 17,O” 5,l 
(2.19(1.01-100)) 
T&Dade 1.5 ng/mL 10.1% 1.9 I,7 9.3’ 3.1 16,7” 5,0 
(1.6 (1.5-37.8)) 
CK 2w U/L 4.5% 4,2 1.6 16,6’ 3,6 25.0” 5,3 
(314 (209.966)) 
CKMBact 24 3.3% 5,6 1,5 16.7’ 3,3 27,7- 5,4 
U/L (62 
(30 - 122)) 
‘PC 0.05 , **p <O.Ol % p=o.o9 
Conclusion The incidence of CKMBmass and troponin is app. 10%. At 3 and 6 months 
follow-up CKMBmass, TnT, Tnl-D, CK and CKMBcat. markerpositive patients had a sig 
nificant increased risk of UAP and repeated revascularfsation. however the figures for 
deaths and AMI’s were low. 
1102-24 Myocsrdial Necrosis Is Halved in Patients Undergoing 
Elective Percutaneous Coronary lnterventlon Who Are 
Pretreated With Lipid-Lowering Therapy 
Herbelt D. AmI Martin J. Quinn, Hitinder S. Gurm, Eric J. Topol, Michael Llncoff, 
Danielle M. Brennan, Michael S. Lauer, Cleveland Clinic Foundation, Cleveland, Ohio. 
Background: Myccardial necrosis occurs commonly after percutaneous coronary inter- 
vention (PCI) and has been associated with increased long-term morbidity and mortality. 
Lipid-lowering agents (LLA) exert multiple effects that might reduce the incidence of myo- 
cardial necrosis after PCI, including plaque stabilization, inhibition of platelet thrombus 
formation and improvement in endothelial function. Nevertheless, it is not known whether 
LLA treatment before PCI is associated with less subsequent myocardial necrosis. 
Methods: We compared the incidence of myocardiat necrosis after elective PCI among 
patients in the EPIC trial who were (n=155) or were not 61~706) on a LLA prior to their 
procedure. A propensity analysis was used to match patients on the probability of treat- 
ment with a LLA prior to their PCI. 
Results: Overall, 16% of patients had post-procedure myocardial necrosis (CK-MB >= 3X 
ULN). LLA pm-treatment was associated with significantly less myocardial necrosis (9 
vs. 17%, Risk Ratio [RR] = 0.49, 95% Cl 0.26-0.62. p=O.O06) [Figure]. After adjusting for 
other potential confounders and the propensity score, LLA pre-treatment was associated 
with significantly less myocardial necrosis (RR = 0.51, 95% Cl 0.25-0.97) p = 0.039). 
Conclusion: Myocardial necrosis was half as likely when patients were on a LLA before 
elective PCI. Randomized data would help determine whether elective PCI should be 
deferred until after the initiation of lipid-lowering therapy. 
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1102-25 Effect of Pre-Procedure Lipid Lowering Therapy on In 
Hospital Mortality Following Percutaneous Coronary 
Interventions: An Analysis of a Large Multicenter 
Database 
Mauro Moscucci, Eva Kline-Rogers, Anthony C. DeFranco, Mictrael D’Dq669U, Ann 
Maxwell-Eward, David Share, John G. McGinnity, Michele De Gregorio, William L. 
Meengs. Vivien L. Clark, Kim A. Eagle, For The Blue Cross Blue Shield of Michigan 
Cardiovascular Consortium (BMCP), University of Michigan, Ann Arbor. Michigan. 
Background: Recent studies have shown a reduction in early mortality in patients with 
acute coronary syndromes discharged home on lipid lowering therapy. The objective of 
our study was to determine the potential effect of pre-procedure lipid lowering therapy 
with statins on in-hospital mortality in patients undergoing percutaneous coronary inter- 
ventions (PCI). 
Methods: We analyzed 16,932 PCI performed between July 1997 and September 2006 
in a consortium of 6 hospitals in Michigan. In-hospital mortality rates in patients who were 
on lipid lowering therapy before the procedure (n=9,064) were compared with those of 
patients who were not (n=7,646). The effect of pre-procedure lipid lowering therapy was 
analyzed using multivariate logistic regression analysis. 
Results: The in-hospital mortality rate was 0.56% in the group of patients who were on 
lipid lowering therapy before the index procedure and 2.6% in the group of patients who 
were not (OR 0.2, 95% Cl 0.14-0.24, p<O.OOl). After adjustment for baseline comorbidi- 
ties, demographic variables, indication for the procedure, severity of underlying coronary 
disease, and for a propensity score for being on lipid lowering therapy, lipid lowering ther- 
apy remained a strong independent predictor of lower in-hospital mortality (Adjusted OR 
0.31, 95% Cl 0.27-0.44). 
Conolusfon: 1) Pm procedure lipid lowering therapy is associated with a significant 
reduction of in hospital mortality following PCI. 2) Although the possibility of bias from 
other unknown confounders cannot be excluded, the strong association between pre- 
procedure lipid lowering therapy and reduced mortality warrants further investigations in 
other registry and prospective studies. 
1102-26 Adrenomedullin as a Predictor of Restenosis and 
Antiintimal Proliferative Hormone in the Patients With 
Coronary Intervention 
BIkenouchi, Nanae Kada, Nobuhiko Itoh, Tokutada Satoh, Yoshiyuki Hada. 
Yasunobu Hirata, Kenji Kangawa. JR Tokyo General Hospital and University of Tokyo, 
Tokyo, Japan, National Cardiovascular Center. Osaka, Japan. 
[Background]: Adrenomedullin (AM) is a vasoactive hormone which is mainly produced in 
arterial endothelial cells especially in the coronary arterial system. It was reported that in 
patients with acute myocardial infarction and congestive heart failure, plasma AM was 
increased. It was also revealed that AM inhibits proliferation and migration of vascular 
